Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI) Head-To-Head Analysis

Javelin Mortgage Investment Corp (NYSE: JMI) and DelMar Pharmaceuticals (NASDAQ:DMPI) are both small-cap shell companies companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility and Risk

Javelin Mortgage Investment Corp has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, DelMar Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Institutional and Insider Ownership

8.1% of DelMar Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Javelin Mortgage Investment Corp and DelMar Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Javelin Mortgage Investment Corp 0 0 0 0 N/A
DelMar Pharmaceuticals 0 1 3 0 2.75

DelMar Pharmaceuticals has a consensus target price of $13.00, indicating a potential upside of 1,447.62%. Given DelMar Pharmaceuticals’ higher possible upside, analysts clearly believe DelMar Pharmaceuticals is more favorable than Javelin Mortgage Investment Corp.

Profitability

This table compares Javelin Mortgage Investment Corp and DelMar Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Javelin Mortgage Investment Corp 59.64% 17.94% 2.30%
DelMar Pharmaceuticals N/A N/A -171.21%

Valuation & Earnings

This table compares Javelin Mortgage Investment Corp and DelMar Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Javelin Mortgage Investment Corp N/A N/A N/A ($0.03) -239.33
DelMar Pharmaceuticals N/A N/A -$8.08 million ($0.69) -1.22

Javelin Mortgage Investment Corp is trading at a lower price-to-earnings ratio than DelMar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dividends

Javelin Mortgage Investment Corp pays an annual dividend of $1.08 per share and has a dividend yield of 15.0%. DelMar Pharmaceuticals does not pay a dividend. Javelin Mortgage Investment Corp pays out -3,600.0% of its earnings in the form of a dividend.

Summary

Javelin Mortgage Investment Corp beats DelMar Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Javelin Mortgage Investment Corp Company Profile

JAVELIN Mortgage Investment Corp. is a real estate investment trust (REIT). The Company invests primarily in fixed rate and hybrid adjustable rate mortgage backed securities. The Company may invest in collateralized commercial mortgage backed securities and other mortgage related investments, including mortgage loans, mortgage related derivatives and mortgage servicing rights. It invests in unsecured notes and bonds issued by government sponsored enterprises (GSEs), the United States Treasuries and money market instruments. The Company is managed by ARMOUR Capital Management LP.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Receive News & Ratings for Javelin Mortgage Investment Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Javelin Mortgage Investment Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply